SOURCE: Addison-Davis Diagnostics, Inc.

August 23, 2005 08:31 ET

/ REPEAT - Addison-Davis Diagnostics Launches Over-the-Counter Sales Initiative With "Parents' Tool" Drug Test Program

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- August 23, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce its strategic Over-The-Counter sales initiative with the new "Parents' Tool" Drug Test Program. The Company will market its proprietary program directly to parents, with a specific focus on mothers, who are concerned about the well being of their children.

The "Parents' Tool" Drug Test, a FDA 510K approved self-contained NIDA (National Institute of Drug Abuse) 5-panel drug test, will be marketed by national retail chains throughout the United States. The "Parents' Tool" drug test will screen for Amphetamines (Crystal Meth), Cocaine, Opiates, Phencyclidine (PCP) and Marijuana (THC).

"We want to become a resource for Parents throughout the country and be viewed as a partner in their fight against drugs in their children's lives. It's time to put families first!" stated Edward W. Withrow III, CEO of Addison-Davis Diagnostics, Inc.

ADDI plans to launch its proprietary "Parents' Tool" program in the first quarter of 2006.

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website www.addisondavis.com or contact Matt Maguire 1-866 THE APPL(E).

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:
    Matt Maguire
    1-866 THE APPL(E)